How hepatitis B spreads and why some infections become chronic
Hepatitis B spreads when infected blood or certain body fluids enter another person's body, including during childbirth, sexual contact or exposure to contaminated needles. The age at which infection occurs is one of the strongest predictors of its long-term outcome: infections acquired in infancy are much more likely to become chronic than those acquired in adulthood.
This explainer examines how hepatitis B spreads, why infections acquired in infancy are more likely to become chronic, how viral DNA persists in liver cells and what long-term liver risks research has documented. It draws on WHO and CDC guidance, age-at-infection studies by Edmunds et al. (1993) and McMahon et al. (1985), and research on viral persistence and liver cancer risk (Revill et al., 2019; Chen et al., 2006).
How does hepatitis B spread from one person to another?
Hepatitis B virus (HBV) is transmitted through infected blood and certain other body fluids. The main routes are transmission from mother to baby around birth, sexual contact, and exposure to infected blood through needles, syringes or sharp instruments. The virus can enter the body even when the amount of infected material is too small to see (WHO, 2026a). Further coverage of infection sits in the health section.
Transmission during childbirth is particularly important globally. In regions where hepatitis B is highly prevalent, many infections occur around birth or in early childhood. In countries with lower prevalence, a larger proportion of new infections occur among adults, often through sexual contact or blood exposure. These differences in transmission patterns help explain the geographical distribution of chronic hepatitis B (WHO, 2026a; WHO, 2026b).
Blood is the most concentrated source of HBV, and exposure through a puncture or break in the skin is an efficient route. Sharing contaminated needles or syringes can transmit the virus. Other possible exposures include reused or inadequately sterilised medical instruments, tattooing or piercing equipment, and accidental needlestick injuries. Sexual transmission can occur through contact with infected semen or vaginal fluids (WHO, 2026a; CDC, 2025a).
HBV can also remain infectious on environmental surfaces for at least seven days, according to the US Centers for Disease Control and Prevention (CDC, 2025b). This matters when contaminated blood is present: a surface does not have to look visibly wet or freshly contaminated for the virus to remain a potential hazard. The available evidence does not establish a universal per-exposure risk or an upper survival limit, so those figures should not be inferred.
A person can transmit HBV without feeling ill. Some infections cause no noticeable symptoms, but the virus may still be present in the blood and other body fluids. The absence of jaundice, abdominal discomfort or other signs therefore does not establish that someone is unable to pass on the infection (WHO, 2026a; CDC, 2025a).
Can hepatitis B pass from a mother to her baby?
Yes. Transmission around childbirth is one of the most important routes of HBV infection worldwide and a major contributor to chronic infection. The likelihood depends partly on the mother's hepatitis B e antigen (HBeAg) status, which is associated with the level of viral replication and infectiousness.
A 2026 review in JAMA reports that, without preventive measures, transmission occurs in approximately 70–90% of infants born to mothers who are positive for both hepatitis B surface antigen (HBsAg) and HBeAg. The corresponding estimate for infants born to HBsAg-positive but HBeAg-negative mothers is 5–20% (Jeng et al., 2026). These ranges should not be treated as universal probabilities: transmission rates vary between populations, and estimates from one region may not apply directly to another.
The importance of maternal infection was demonstrated in an early study in Taiwan. Researchers followed 158 babies born to mothers who were asymptomatic hepatitis B carriers. Sixty-three babies developed evidence of hepatitis B antigen in their blood, and 51 of those infections were detected within the first six months of life. The study identified several maternal and early-life factors associated with transmission, helping establish the importance of infection around birth (Stevens et al., 1975).
Hepatitis B is not ordinarily transmitted through breastfeeding. A study of 147 babies born to mothers carrying HBsAg found that the rates of infection were almost identical among breastfed and non-breastfed infants. The researchers also found no HBsAg in 32 breast-milk samples. Modern CDC guidance similarly describes transmission through breast milk as unlikely (Beasley et al., 1975; CDC, 2025a).
The distinction between transmission at birth and transmission through ordinary contact is important. HBV can be present in saliva, but it is not considered a route of transmission through kissing or sharing eating utensils. The virus is also not spread through coughing, sneezing, hugging, or sharing food and water. Saliva may be relevant when infected blood is present, such as with open cuts or sores, but it is not an efficient route in everyday social contact (WHO, 2026a; CDC, 2025a).
Other viruses spread through different routes. For comparison, research on RSV transmission examines respiratory particles and contact with contaminated surfaces, illustrating why transmission patterns established for one virus should not automatically be applied to another.
How likely is hepatitis B to become chronic at different ages?
Age at infection has a striking association with whether hepatitis B becomes chronic. The younger a person is when infected, the greater the likelihood that the virus will persist. The difference is particularly pronounced between infants and immunocompetent adults.
The CDC estimates that around 90% of infected infants develop chronic hepatitis B. Among children infected between one and five years of age, the proportion is approximately 30%. For immunocompetent adolescents and adults, the risk is much lower: the CDC's clinical overview reports that about 95% of infected adults recover completely from acute infection (CDC, 2025a; CDC, 2025b).
Age at infection | Outcome | Source |
Infants | Around 90% develop chronic hepatitis B | CDC, 2025a; CDC, 2025b |
Children aged one to five | Approximately 30% develop chronic infection | CDC, 2025a; CDC, 2025b |
Immunocompetent adults | Around 95% of primary infections are self-limited | CDC, 2025b |
Four years or younger (Alaska cohort) | 28.8% became carriers | McMahon et al., 1985 |
30 years or older (Alaska cohort) | 7.7% became carriers | McMahon et al., 1985 |
Note: these figures are the share of infections that become chronic at each age at infection, not an individual's risk. The Alaska percentages come from one cohort, while the CDC entries summarise several sources.
The World Health Organization presents the age pattern in a broader way. Its 2026 hepatitis B fact sheet states that infection acquired in adulthood becomes chronic in fewer than 5% of cases, while infection in infancy and early childhood leads to chronic hepatitis in about 95% of cases (WHO, 2026a). The two bodies describe the age groups differently, and the figures are not directly comparable: WHO gives a single estimate for infancy and early childhood, while the CDC reports babies and children aged one to five separately.
Chronic hepatitis B is generally defined by the persistence of hepatitis B surface antigen in the blood for more than six months. An acute infection, by contrast, may resolve as the immune system clears the virus. Many adults with acute hepatitis B recover without developing a chronic infection, although the outcome varies with age and immune status (CDC, 2025a; Jeng et al., 2026).
Two studies help show how the age gradient was established. In a 1993 analysis, Edmunds and colleagues combined serological surveys and used a mathematical model to estimate the probability that infection would lead to a persistent carrier state. Their estimate was approximately 0.885 for infection acquired around birth, with a sharp decline through childhood and a probability of about 0.1 by adulthood (Edmunds et al., 1993).
A separate prospective study followed 1,280 initially seronegative Yupik people in south-western Alaska between 1971 and 1976. Of those who developed serological evidence of infection, the likelihood of becoming a chronic carrier was inversely related to age. Among people infected at four years or younger, 28.8% became carriers, compared with 7.7% of those infected at age 30 or older. The pattern was not simply that younger people were more likely to become infected: age was associated with what happened after infection (McMahon et al., 1985).
The same study found a seemingly paradoxical pattern in clinical symptoms. Clinically apparent hepatitis was less common among the youngest infected people and more common among adults. In other words, an adult infection was more likely to cause noticeable acute illness but less likely to persist. A baby might show few obvious signs while remaining infected for life (McMahon et al., 1985).
Why can hepatitis B persist in the body for decades?
The virus has a biological feature that makes long-term persistence possible: covalently closed circular DNA, usually abbreviated as cccDNA. After HBV enters a liver cell, its genetic material reaches the nucleus. There, it is converted into a stable circular DNA form that acts as a template for producing viral RNA and proteins (Liang, 2009).
The cccDNA reservoir is particularly important because it can remain inside infected liver cells even when viral replication is suppressed. It is relatively resistant to both immune clearance and the effects of current antiviral medicines. Researchers therefore regard it as one of the central obstacles to achieving a complete cure for chronic hepatitis B (Revill et al., 2019; Liang, 2009).
HBV also replicates through an RNA intermediate and can integrate parts of its DNA into the genetic material of a host cell. Integrated viral DNA is not the same as cccDNA and does not independently reproduce a complete virus in the same way. However, it can contribute to the production of hepatitis B surface antigen. This adds another layer of complexity to the biology of persistent infection (Liang, 2009).
The presence of viral material in liver cells does not mean that every infected cell is continuously destroyed. Research indicates that immune mechanisms can suppress viral replication without killing all infected cells. This distinction matters because liver injury in hepatitis B is closely connected to the host immune response, not simply to direct viral destruction of liver tissue (Revill et al., 2019).
Current antiviral medicines can suppress HBV replication and reduce the risk of disease progression, but they rarely eliminate the cccDNA reservoir. This is why treatment may control chronic infection without removing every trace of the virus. Researchers use the term functional cure for a key goal in this field, but it is not the same as complete eradication of all viral material (Revill et al., 2019; Liang, 2009).
Vaccination and treatment address different questions. A historical rabies vaccine experiment investigated antibody responses to an inactivated viral preparation, rather than the removal of an established infection or persistent viral reservoir.
Is the immune system of a baby unable to recognise hepatitis B?
The age gradient is well established, but its exact biological explanation is not. A traditional account described infants as developing immune tolerance to HBV: the immune system would supposedly recognise the virus as something it should not attack, allowing infection to persist. This explanation is now considered too simple. How far a vaccination programme can push a virus out of circulation is set out in an account of the present status of polio vaccines.
Some human studies have challenged the idea that young people with chronic hepatitis B have no meaningful virus-specific immune response. Kennedy and colleagues detected HBV-specific T cells in children and young adults and found that their immune profiles were not consistent with complete T-cell tolerance. Mason and colleagues also reported signs of viral DNA integration and expansion of liver-cell clones in people previously classified as being in an immune-tolerant phase (Kennedy et al., 2012; Mason et al., 2016).
These findings do not mean that the immune response is fully effective. Rather, they suggest that the label of immune tolerance may hide a more complicated state in which viral replication is high but inflammation is relatively limited. The immune system may recognise HBV without being able to control it effectively.
One proposed explanation for the age effect comes from experiments involving mice. Publicover and colleagues found that the organisation of immune cells in the liver differed between young and adult animals. In their model, adult livers were better able to organise immune responses associated with viral clearance.
The researchers also examined a small number of human samples, but the main mechanistic findings came from the mouse experiments. They cannot yet establish that the same process explains the age gradient in people (Publicover et al., 2013).
The most defensible conclusion is therefore narrower than the traditional explanation: age at infection strongly predicts chronicity, but researchers have not established one complete mechanism that explains why. Differences in immune development, viral exposure and the interaction between HBV and liver cells may all contribute.
What can chronic hepatitis B mean for the liver over time?
Many people with chronic hepatitis B have no obvious symptoms for years. The infection can nevertheless cause ongoing liver inflammation and, in some people, progressive scarring. Over time, advanced scarring can lead to cirrhosis, while chronic infection also increases the risk of hepatocellular carcinoma, the most common type of primary liver cancer (WHO, 2026a; CDC, 2025b).
The long-term risk is not identical for everyone with chronic HBV. Viral activity, age, liver inflammation and other factors are associated with disease progression. A major prospective study in Taiwan, known as REVEAL-HBV, followed 3,653 people who were HBsAg-positive and did not have hepatitis C.
Over an average of 11.4 years, researchers recorded 164 cases of hepatocellular carcinoma. The incidence increased with baseline HBV DNA levels, showing a dose-response relationship between viral load and liver cancer risk (Chen et al., 2006).
The association remained after the researchers accounted for several other factors, including age, sex, smoking, alcohol use, HBeAg status, alanine aminotransferase levels and cirrhosis at the beginning of the study. The findings helped establish that viral replication is an important marker of long-term risk, even among some people without obvious signs of advanced liver disease (Chen et al., 2006).
The World Health Organization estimated that 240 million people were living with chronic hepatitis B in 2024. The same report estimated 0.9 million new infections and 1.1 million HBV-related deaths in that year, mostly from cirrhosis and liver cancer (WHO, 2026b). These 2024 estimates were published in 2026, and the organisation cautions that changes in modelling and calibration mean they should not be directly compared with estimates in earlier reports. Within its own recalibrated series WHO reports that the number of people living with chronic hepatitis B fell by 19 million, or 7.4%, between 2015 and 2024 (WHO, 2026b).
Population-level evidence also shows how the age pattern affects the global burden. In regions where infection is commonly acquired during birth or early childhood, a larger share of infections can become chronic. In regions where transmission occurs more often in adulthood, most infections are cleared. Age at infection is one contributor to the persistence of high prevalence across generations, alongside vaccination coverage and access to prevention services (WHO, 2026a).
What is established about hepatitis B, and what remains uncertain?
The evidence is strong that hepatitis B spreads through infected blood and certain body fluids, and that transmission around birth is a major source of chronic infection worldwide. Studies across different populations consistently show that the risk of chronicity falls sharply as the age at infection increases. The exact percentages vary by age group and source, but the overall pattern is consistent (WHO, 2026a; CDC, 2025a; Edmunds et al., 1993; McMahon et al., 1985).
The persistence of cccDNA in liver-cell nuclei is also well established as a major obstacle to complete viral eradication. Long-term cohort research links higher HBV DNA levels with increased risks of cirrhosis and liver cancer. These findings help explain why chronic hepatitis B can remain clinically important even when a person feels well (Revill et al., 2019; Liang, 2009; Chen et al., 2006).
What remains uncertain is the precise immune mechanism behind the age effect. The classic idea of complete immune tolerance in infants is contested by human studies, while some proposed explanations rely on animal experiments or laboratory models (Kennedy et al., 2012; Mason et al., 2016; Publicover et al., 2013).
The distinction matters: an established epidemiological pattern does not automatically prove the biological explanation behind it. Researchers know that infection in infancy is much more likely to become chronic than infection in adulthood. They are still working out exactly how age, immune development and the virus's persistence mechanisms combine to produce that difference.
The age at infection is one of the strongest predictors of whether hepatitis B becomes chronic: around nine in ten infected infants develop persistent infection, compared with fewer than one in twenty immunocompetent adults (CDC, 2025b).
Frequently asked questions
Can hepatitis B spread if a person has no symptoms?
Yes. People with hepatitis B can transmit the virus even when they feel well and have no noticeable symptoms. The infection may be asymptomatic, particularly in its early stages, so the absence of jaundice or other signs does not show whether HBV is present or whether transmission is possible.
Can you catch hepatitis B from kissing or sharing food?
Ordinary social contact does not spread hepatitis B. The virus may be detectable in saliva, but kissing, sharing utensils, hugging, coughing and sharing food or water are not considered routes of transmission. The main documented routes involve infected blood, sexual contact and transmission around childbirth.
How many people have hepatitis B worldwide?
The World Health Organization estimated that 240 million people were living with chronic hepatitis B in 2024. Its 2026 report also estimated 0.9 million new infections and 1.1 million related deaths during that year. The organisation warns that the updated estimates should not be compared directly with earlier reports.
Why is hepatitis B more common in some parts of the world?
Because the age at which people are infected differs between regions. Where transmission often happens around birth or in early childhood, a large share of infections becomes chronic and the virus continues to circulate. Where most infections occur in adulthood, the immune system usually clears them, so prevalence stays lower.
Can chronic hepatitis B be completely cured?
Current antiviral medicines can suppress hepatitis B replication and reduce liver damage, but they rarely eliminate the cccDNA reservoir inside liver cells. Researchers distinguish a functional cure, meaning sustained loss of hepatitis B surface antigen and undetectable HBV DNA after treatment has been stopped, from complete removal of viral material. These are different goals, and a complete cure remains difficult.
Can hepatitis B survive outside the body?
The CDC states that HBV can remain infectious on environmental surfaces for at least seven days. This is relevant when infected blood contaminates a surface. The available sources do not establish a reliable upper survival limit or a universal probability of infection from a particular surface exposure (CDC, 2025b).
Sources
- World Health Organization. Hepatitis B. Fact sheet, 28 July 2026. www.who.int/news-room/fact-sheets/detail/hepatitis-b
- World Health Organization. Global hepatitis report 2026. Geneva: World Health Organization; 28 April 2026. www.who.int/publications/i/item/9789240122383
- Centers for Disease Control and Prevention. Hepatitis B Basics. 10 November 2026. www.cdc.gov/hepatitis-b/about/index.html
- Centers for Disease Control and Prevention. Clinical Overview of Hepatitis B. 2 November 2026. www.cdc.gov/hepatitis-b/hcp/clinical-overview/index.html
- Jeng WJ, Yip TC, Lok AS. Hepatitis B: a review. JAMA. 2026;335(21):1879–1892. DOI 10.1001/jama.2026.6070.
- Stevens CE, Beasley RP, Tsui J, Lee WC. Vertical transmission of hepatitis B antigen in Taiwan. New England Journal of Medicine. 1975;292(15):771–774. DOI 10.1056/NEJM197504102921503.
- Beasley RP, Stevens CE, Shiao IS, Meng HC. Evidence against breast-feeding as a mechanism for vertical transmission of hepatitis B. The Lancet. 1975;2(7938):740–741. DOI 10.1016/S0140-6736(75)90724-2.
- Edmunds WJ, Medley GF, Nokes DJ, Hall AJ, Whittle HC. The influence of age on the development of the hepatitis B carrier state. Proceedings of the Royal Society B. 1993;253(1337):197–201. DOI 10.1098/rspb.1993.0102.
- McMahon BJ, Alward WL, Hall DB, et al. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. Journal of Infectious Diseases. 1985;151(4):599–603. DOI 10.1093/infdis/151.4.599.
- Revill PA, Chisari FV, Block JM, et al. A global scientific strategy to cure hepatitis B. The Lancet Gastroenterology and Hepatology. 2019;4(7):545–558. DOI 10.1016/S2468-1253(19)30119-0.
- Liang TJ. Hepatitis B: the virus and disease. Hepatology. 2009;49(5 Suppl):S13–S21. DOI 10.1002/hep.22881.
- Kennedy PTF, Sandalova E, Jo J, et al. Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B. Gastroenterology. 2012;143(3):637–645. DOI 10.1053/j.gastro.2012.06.009.
- Mason WS, Gill US, Litwin S, et al. HBV DNA integration and clonal hepatocyte expansion in chronic hepatitis B patients considered immune tolerant. Gastroenterology. 2016;151(5):986–998.e4. DOI 10.1053/j.gastro.2016.07.012.
- Publicover J, Gaggar A, Nishimura S, et al. Age-dependent hepatic lymphoid organization directs successful immunity to hepatitis B. Journal of Clinical Investigation. 2013;123(9):3728–3739. DOI 10.1172/JCI68182.
- Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295(1):65–73. DOI 10.1001/jama.295.1.65.
This article is for general information and is not medical advice. It was reviewed for accuracy by a qualified clinician; decisions about your health should be made with your own doctor.
Related
Polio vaccines in 1960: what the debate got right and wrong
UV-Inactivated Sheep-Brain Rabies Vaccine: A 1975 Experiment
How RSV spreads: lessons from a 1981 transmission study
Common cold symptoms and why rhinoviruses cause them
How staph infections start on the skin and reach the blood
How Cardiolipin Helped Standardize Syphilis Serology
Partner Violence and Condom Use in HIV-Discordant Couples